Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.9702
-0.0498 (-4.88%)
At close: Aug 13, 2025, 4:00 PM
0.9734
-0.0092 (-0.94%)
Pre-market: Aug 14, 2025, 8:47 AM EDT
AKTX's stock price has decreased by -71.13% in the past year and price targets may not have had time to catch up.
Akari Therapeutics, Analyst Ratings
Total Analysts
1
Consensus Rating
Strong Buy
Price Target
$5.00
Upside
+415.36%
Ratings History
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +415.36% | Jul 18, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +2,992.15% | Dec 5, 2022 |
Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +8,145.72% | Nov 1, 2022 |
B. Riley Securities | B. Riley Securities | Strong Buy Maintains $140 → $100 | Strong Buy | Maintains | $140 → $100 | +10,207.15% | Mar 13, 2020 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $300 → $160 | Strong Buy | Maintains | $300 → $160 | +16,391.45% | Mar 29, 2018 |
B. Riley Securities | B. Riley Securities | Hold Initiates $60 | Hold | Initiates | $60 | +6,084.29% | Feb 8, 2018 |
William Blair | William Blair | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Sep 22, 2017 |
Chardan Capital | Chardan Capital | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | May 31, 2017 |
William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 12, 2017 |
Chardan Capital | Chardan Capital | Strong Sell Reiterates $100 → $130 | Strong Sell | Reiterates | $100 → $130 | +13,299.30% | Apr 17, 2017 |
Chardan Capital | Chardan Capital | Strong Sell Initiates $100 | Strong Sell | Initiates | $100 | +10,207.15% | Jul 11, 2016 |